TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01796470
Drug: Entospletinib
Normalized name: Entospletinib
DrugBank: Entospletinib (DB12121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entospletinib tablets administered orally twice daily
Study: NCT01796470
Drug: Idelalisib
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idelalisib tablets administered orally twice daily
Study: NCT00449800
Drug: ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00831155
Drug: Nicotine Patches, Denicotinized Cigarettes
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both groups will receive standard Nicotine Replacement Therapy after the quit date. The Extinction Based group will receive Nicotine patches and denicotinized cigarettes before their quit date
Study: NCT02226653
Drug: Evacetrapib
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03295786
Drug: Cerebral Dopamine Neurotrophic Factor
Normalized name: Cerebral dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated intracerebral infusions
Study: NCT00003192
Drug: aminocamptothecin
Normalized name: Aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00684554
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose is determined according to the participants' individual need.
Study: NCT00003158
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003158
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003158
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00104403
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00104403
Drug: Ondansetron Hydrochloride
Normalized name: Ondansetron Hydrochloride
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01299961
Drug: abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 125 mg once a week up to 12 months.
Study: NCT01485367
Drug: adapalene gel 0.3%
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A pea size drop of Adapalene gel 0.3% will be applied to the odd numbered subjects on the left dorsal hand \& extensor forearm. A pea size drop of Adapalene gel 0.3% will be applied to the even numbered subjects on the right dorsal hand \& extensor forearm. The randomized area will be cleansed with Cetaphil Gentle Cleanser before applying the study medication. All subjects will apply sunscreen with zinc oxide in the morning to both the right \& left forearms.
Study: NCT01337310
Drug: Tesetaxel
Normalized name: Tesetaxel
DrugBank: Tesetaxel (DB12019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose for the first 3 patients treated will be 24 mg/m2. In the absence of dose-limiting toxicity, the dose will be increased by 3 mg/m2 for the next group of 3 patients treated. Interpatient dose escalation will continue in this manner to 27 and 31 mg/m2 until the maximum tolerated dose or the maximum dose allowed per protocol (31 mg/m2) is reached and 6 patients are treated at this dose.
Study: NCT01064622
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01064622
Drug: Vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00394628
Drug: AQ4N
Normalized name: Tirapazamine
DrugBank: Tirapazamine (DB04858)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00394628
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01525550
Drug: sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.
Study: NCT02471677
Drug: Elonva
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: corifollitropin alfa (Elonva): a single injection 100 or 150 ug (depending on patient body weight) on Day 2/3 of menstrual cycle
Study: NCT02471677
Drug: Puregon
Normalized name: Puregon
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: follitropin beta (Puregon): daily injections 150 IU from Day 2/3 of menstrual cycle until adequate follicle development is achieved
Study: NCT00964678
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice daily oral treatment in escalating dose
Study: NCT03359395
Drug: Alfentanil
Normalized name: Alfentanil
DrugBank: Alfentanil (DB00802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
Study: NCT00100477
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00100477
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02144818
Drug: Decapeptyl
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triggering with GnRH agonist
Study: NCT02122185
Drug: metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03648372
Drug: TAK-981
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion.
Study: NCT02850406
Drug: Voxelotor
Normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Part A: Voxelotor will be administered as oral capsules or tablets~* Part B: Voxelotor will be administered as oral capsules or tablets~* Part C: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension~* Part D: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension
Study: NCT04317534
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 400mg IV
Study: NCT03586453
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients who fulfill eligibility criteria will be entered into the trial to receive Osimertinib.~After the screening procedures confirm participation in the research study:~* Osimertinib: Oral, Daily 28 day cycle.~* Radiographic assessment: every 2 cycles for first 6 months and then every 3 cycles until disease progression.~* Tumor biopsy between C4 and C8 and at disease progression
Study: NCT03508440
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Steroid
Study: NCT02014103
Drug: Prograf
Normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of each formulation will be determined by sequence.
Study: NCT02014103
Drug: Tacrolimus, Sandoz
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of each formulation will be determined by sequence.
Study: NCT02014103
Drug: Tacrolimus, Reddy Laboratory
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of each formulation will be determined by sequence.
Study: NCT02014103
Drug: Tacrolimus, Mylan
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of each formulation will be determined by sequence.
Study: NCT02014103
Drug: Tacrolimus, Accord
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of each formulation will be determined by sequence.
Study: NCT02014103
Drug: Tacrolimus, Pancea Biotech Limited
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of each formulation will be determined by sequence.
Study: NCT04070040
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
Study: NCT00138242
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00138242
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01153542
Drug: VX-770
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In period 1, subjects will receive a single oral dose of desipramine on Day 1.
Study: NCT01153542
Drug: VX-770
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In period 2, subjects will receive 150 mg VX-770 q12h orally from the morning of Day 1 through the evening of Day 9. Subjects will receive 50 mg Desipramine as a single dose on Day 5 of period 2.
Study: NCT04021368
Drug: RVU120(SEL120)
Normalized name: SEL120-34A free base
DrugBank: SEL120-34A free base (DB18107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVU120(SEL120) will be administered as a single oral dose every other day (q.o.d.) for a total of 7 doses i.e. on Days 1, 3, 5, 7, 9, 11 and 13, in a 3-week treatment cycle.
Study: NCT01027754
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Days 1-3: 0.5 mg once a day Days 4-7: 0.5 mg twice a day Days 8-84: 1 mg twice a day
Study: NCT03966118
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 1mg/kg Day 1 and Day 15 of a 28-day cycle
Study: NCT03966118
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab 8mg/kg on Day 1 and Day 15 of a 28-day cycle
Study: NCT03966118
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80mg/m2 on Day 1, Day 8 and Day 15 of a 28-day cycle
Study: NCT00594308
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg/m2/day for 5 consecutive days
Study: NCT00594308
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg/kg/day will be given by continuous intravenous infusion beginning on Day -1.
Study: NCT00594308
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg will be administered through day +60 and then discontinued if there is no GVHD.
Study: NCT00594308
Drug: Basiliximab
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20mg , will be given by intravenous infusion (without an in-line filter) over at least 15 minutes beginning 3 days after engraftment.
Study: NCT01882829
Drug: dextromethorphan/quinidine
Normalized name: DEXTROMETHORPHAN/QUINIDINE
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: up to 45/10 mg every 12 hours in patients with TRD with a short 7 day tapering period in which subjects are tapered off 45/10 mg dose from twice a day to once daily for an additional 7 days at post 8-week treatment period to minimize the potential for discontinuation effects
Study: NCT02673060
Drug: MBC-11
Normalized name: 4-MBC
DrugBank: Enzacamene (DB11219)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg/kg-10 mg/kg , IV (in the vein) on day 1-5 of each 28 day cycle. Number of cycles: 2, in case of partial metabolic reaction or stable metabolic reaction - up to 4.
Study: NCT03829488
Drug: Plasma-Lyte 148 (approx. pH 7.4) IV Infusion
Normalized name: Plasma-lyte 148
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasma-Lyte 148 (approx. pH 7.4) IV Infusion is a sterile, clear, non-pyrogenic isotonic solution and when administered intravenously is a source of water, electrolytes and calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water \& electrolytes or as an alkalinising agent.
Study: NCT03829488
Drug: 0.9% SODIUM CHLORIDE 9g/L injection BP
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride (0.9% saline) infusion is a sterile, non-pyrogenic solution of sodium chloride in Water for Injections. The concentration of sodium chloride is 154mmol/L. Sodium chloride (0.9%) intravenous infusion is indicated for extra-cellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.
Study: NCT01480765
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days
Study: NCT01480765
Drug: Ketamine infusion
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1mg/kg/hr for 48 hours post operatively
Study: NCT03635996
Drug: Etripamil NS 70 mg
Normalized name: NS-2359
DrugBank: Etripamil (DB12605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive a total of 200 micro-liters of etripamil NS 70 mg via the Aptar Pharma Nasal Spray Bidose System each time they self-administer study drug.
Study: NCT04178863
Drug: Latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: latanoprost IOP reduction
Study: NCT03092011
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours Clonidine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
Study: NCT03092011
Drug: Morphine Sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours Morphine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
Study: NCT04421664
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
Study: NCT01744366
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01744366
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02534623
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02534623
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02534623
Drug: sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00485342
Drug: Peg-interferon alpha 2a and ribavin
Normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight \< 75 kg and 1200 mg/day if weight ≥ 75 kg).~Duration of treatment : 48 weeks Duration of study for patients : 72 weeks
Study: NCT00485342
Drug: ribavirin with adaptation dose
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC.~The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks
Study: NCT02012777
Drug: propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent. This will be administered in an open-label single administration to 3 cohorts (10mg, 20mg, and 40mg) of children with sickle cell disease. Patient blood will be evaluated for red cell adhesion and patient data evaluated for safety monitoring.
Study: NCT01832038
Drug: Lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Strength: Lacosamide (LCM) 50 mg, LCM 100 mg~Formulation: Tablet~Frequency: twice daily during the study period (until the date of approval)~At the completion of EP0008 \[NCT01710657\], all subjects who choose to enroll in EP0009 will be taking a dose of Lacosamide 200 mg/day. At the beginning of EP0009, the investigator may maintain the LCM dose or increase or decrease the dose. During the Treatment Period, the investigator will be allowed to increase or decrease the dose of LCM to optimize tolerability and seizure reduction. The LCM dose may be decreased to 100 mg/day or increased, no faster than 100 mg/day per week, up to 400 mg/day.
Study: NCT01283932
Drug: Pantoprazole Sodium
Normalized name: Pantoprazole Sodium
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole Sodium DR Tablets 40 mg
Study: NCT00004228
Drug: asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00004228
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00004228
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00004228
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00004228
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00004228
Drug: thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03290950
Drug: daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cycle 1 ONLY: Daratumumab 16 mg/kg days 1, 8, 15, and 22, Cycle 2: Daratumumab 16mg/kg days 1, 8, 15, and 22; Cycles 3-6: Daratumumab 16mg/kg days 1 and 15, Cycles 7-8: Daratumumab 16mg/kg day 1; Daratumumab rate of infusion is per MSKCC guidelines.
Study: NCT03290950
Drug: carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 2 and 3; Carfilzomib 36 mg/m2 per dose, days 8, 9, 15, and 16; Cycles 2-8: Carfilzomib 36 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
Study: NCT00004228
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00963885
Drug: Copegus
Normalized name: Copegus
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 or 1200mg po daily for 24 or 48 weeks
Study: NCT00963885
Drug: Pegasys
Normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180micrograms sc weekly for 24 or 48 weeks
Study: NCT00963885
Drug: RO5190591 (Danoprevir)
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg po q8h for 12 weeks
Study: NCT00963885
Drug: RO5190591 (Danoprevir)
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg po q12h for 12 weeks
Study: NCT00963885
Drug: RO5190591 (Danoprevir)
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900mg po q12h for 12 weeks
Study: NCT00963885
Drug: RO5190591 (Danoprevir)
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks
Study: NCT01509404
Drug: Valganciclovir
Normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Valcyte per package insert guidelines for 200 days post transplant
Study: NCT01509404
Drug: Valganciclovir
Normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
Study: NCT03290950
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cycle 1 ONLY: Lenalidomide 25 mg/day, days 2-21 every 28 days; Cycles 2-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
Study: NCT03290950
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 2, 3, 8, 9, 15, 16, Cycles 2: Dexamethasone 20mg/dose, days 1, 2, 8, 9, 15, 16 and 22; Cycles 3-4: Dexamethasone 20mg/dose, days 1,2,8,9,15 and 16, Cycles 5- 8: Dexamethasone 10mg/dose, days 1, 2, 8, 9, 15, and 16
Study: NCT00185614
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Filgrastim 10 µg/kg/day to mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion (Auto-HCT)~* Filgrastim 5 µg/kg/day starting 6 days after melphalan (Day 4 after Auto-HCT)~* Filgrastim 16 µg/kg/day to mobilize donor peripheral blood progenitor cells (PBPC) for allogeneic transplant (Allo-HCT)
Study: NCT00185614
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 200 mg/m2 (high-dose) intravenously as conditioning for Auto-HCT